Country | Vitamin K prophylaxis | Incidence of HDN per 100,000 infants, RR (95% CI) |
---|---|---|
Denmark | ||
 1994 to June 2000 | 2 mg po at birth, 1 mg po weekly for 3 months | 0.0 (0 to 0.9) |
 After June 2000 | 2 mg IM at birth | Not available |
France | 2 mg po weekly for 6 weeks | Not available |
Germany | 2 mg po for 3 doses: days 1, 4–10 and 28–42 | 0.44 (0.2 to 0.9) |
Netherlands | (A) 1 mg po at birth, 25 μg po daily from week 2 to 13 (B) 1 mg po at birth, 150 μg po daily from week 2 to 13 | (A) 3.2 (1.2 to 6.9) Intracranial HDN, general and targeted surveillance (A) 1.6 (0.4 to 5.1) and 3.1 (1.9 to 5.0) (B) 1.3 (0.5 to 3.2) and 1.2 (0.6 to 2.3) |
United Kingdom | 1 mg IM at birth | 0.1 |
2 mg po for 3 doses: day 1, weeks 1 and 4 | 0.43 | |
Spain | 1 mg IM at birth | ‘Almost inexistent’a |
Switzerland | 2 mg po for 3 doses: day 1, day 4, week 4 | 0.0 (0.0 to 0.81)b [16] 1.09 (0.4 to 2.6) [17] |